CDTX - Cidara Therapeutics, Inc.
| Previous Close | 2.3000 |
| Open | 2.2900 |
| Bid | 2.2800 x 1000 |
| Ask | 2.3000 x 1000 |
| Day's Range | 2.2200 - 2.3500 |
| 52 Week Range | 1.9400 - 6.3500 |
| Volume | 90,167 |
| Avg. Volume | 97,464 |
| Market Cap | 63.977M |
| Beta (3Y Monthly) | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7580 |
| Earnings Date | May 12, 2017 - May 15, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.00 |
- Business Wire•9 days ago
Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, highlighted new data from multiple studies of rezafungin, the company’s lead investigational compound, this week during the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. Rezafungin is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Three oral presentations at ECCMID showcased results from nonclinical and in vivo studies that demonstrate the potential of rezafungin to fight and protect against difficult-to-treat fungal infections.
- Business Wire•10 days ago
Cidara Therapeutics Selects First Clinical Development Candidate from its Cloudbreak Influenza (Antiviral) Program
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has selected the antiviral conjugate (AVC) CB-012 as its first clinical development candidate from the company’s Cloudbreak® influenza (antiviral) program. Data supporting the selection will be presented today in an oral session at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). CB-012 is a novel conjugate of a highly potent antiviral agent linked to a human antibody fragment.
- PR Newswire•13 days ago
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
- GlobeNewswire•22 days ago
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 11:20 a.m. EDT (8:20 a.m. PDT) in New York City. Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial, for the treatment of candidemia and invasive candidiasis and continues to discuss with regulatory authorities its plans for the design and the initiation of a second Phase 3 trial in the prophylaxis of invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation.
- Business Wire•last month
Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin
- Business Wire•2 months ago
Cidara Therapeutics Announces Rezafungin Presentations at the 2019 European Society for Blood and Marrow Transplantation Meeting
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that three rezafungin abstracts have been accepted for presentation at the 45th Annual European Society for Blood and Marrow Transplantation (EBMT) Meeting to be held in Frankfurt, Germany from March 24-27, 2019. Rezafungin is a novel echinocandin antifungal and is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. “Patients undergoing blood and marrow transplantation are at increased risk of acquiring deadly invasive fungal infections and current prevention strategies require multiple antifungals that are associated with known drug-drug interactions as well as safety and tolerability issues,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
- Simply Wall St.•2 months ago
Have Insiders Been Buying Cidara Therapeutics, Inc. (NASDAQ:CDTX) Shares?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examplesRead More...
- GlobeNewswire•2 months ago
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
SAN DIEGO, Feb. 28, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported.
- Business Wire•3 months ago
Cidara Therapeutics Announces Rezafungin Presentations at the 2019 Transplantation and Cellular Therapy (TCT) Meeting
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from studies of its lead antifungal rezafungin will be presented at the 2019 Transplantation and Cellular Therapy (TCT) Meeting of ASBMT and CIBMTR (formerly the BMT Tandem Meetings) to be held in Houston, Texas from February 20-24, 2019. “The TCT meeting is an important venue for Cidara to share data that demonstrate the potential advantages of rezafungin for the prevention of invasive fungal infections in blood and marrow transplant patients,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. Invasive fungal infections (IFIs) are a leading cause of morbidity and mortality among immunocompromised patients, particularly those undergoing blood and marrow transplantation.
- PR Newswire•3 months ago
Antimicrobials Working Group Announces Updates to Leadership Team
WASHINGTON , Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh , M.D., President, Chief Operating Officer and Chief Medical ...
- Simply Wall St.•4 months ago
How Does Investing In Cidara Therapeutics, Inc. (NASDAQ:CDTX) Impact The Volatility Of Your Portfolio?
If you're interested in Cidara Therapeutics, Inc. (NASDAQ:CDTX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
- Business Wire•5 months ago
Cidara Therapeutics Appoints James Levine as CFO and Jessica Oien as General Counsel and Secretary
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointments of James (Jamie) Levine as chief financial officer and Jessica Oien, J.D., as general counsel and secretary. “We are extremely pleased to welcome Jamie and Jessica to our executive management team.
- Zacks•5 months ago
Cidara Therapeutics (CDTX) Enters Oversold Territory
Cidara Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Business Wire•5 months ago
Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal infections in bone marrow transplantation (BMT) patients at the 60th American Society of Hematology (ASH) Annual Meeting. The 2018 ASH Meeting will be held December 1-4 in San Diego. The rezafungin ASH abstract (2071), titled “Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis Dose Selection for Prevention of Invasive Fungal Infections for Bone Marrow Transplant Patients," will be presented in a poster session on Saturday, December 1.
- GlobeNewswire•5 months ago
New Research Coverage Highlights Alcentra Capital, VeriSign, Americold Realty Trust, Internet Initiative Japan, DAVIDsTEA, and Cidara Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•5 months ago
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the second consecutive year. Cidara ranked among the top 15 small companies, and the number one ranked biotech in the small company category, in the San Diego Metro Area. “We are once again honored to be recognized as a top workplace by our employees, whose feedback reflects our commitment to nurturing a positive work environment where we are true to our values and advocate for integrity, collaboration, urgency, accountability and courage,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
- Associated Press•6 months ago
Cidara Therapeutics: 3Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 49 cents. In the final minutes of trading on Thursday, the company's shares hit $4.13. A year ago, they were trading at $7.95. _____ ...
- GlobeNewswire•6 months ago
Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results
SAN DIEGO, Nov. 08, 2018 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported.
- Business Wire•6 months ago
Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress
Cidara Therapeutics, Inc. , a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new antiviral program at the upcoming World Antimicrobial Resistance Congress taking place October 25-26, 2018 in Washington, DC.
- Business Wire•6 months ago
Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be held in Mestre, Venice from October 25-26, 2018. Rezafungin is the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. Hot Topics in Infectious Diseases (HTIDE) is a bi-annual conference which convenes more than 400 delegates from all over the world to discuss topics on novel approaches to diagnosis and treatment of infectious diseases.
- Business Wire•7 months ago
Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the presentation of data from the company’s Phase 2 STRIVE trial of rezafungin at IDWeek 2018, taking place in San Francisco from October 3-7. The STRIVE trial successfully achieved its primary endpoints, demonstrating the efficacy and safety of once-weekly dosing of rezafungin compared to once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis.
- Business Wire•7 months ago
Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal, rezafungin, to treat candidemia and invasive candidiasis. Rezafungin is a novel echinocandin antifungal being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. “Difficult-to-treat, invasive Candida infections are associated with a high mortality and affect the most vulnerable patients.
- Simply Wall St.•7 months ago
Shareholders Should Check If Insiders Own Shares In Cidara Therapeutics Inc (NASDAQ:CDTX)
The big shareholder groups in Cidara Therapeutics Inc (NASDAQ:CDTX) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders ownRead More...
- Business Wire•7 months ago
FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program
Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the company’s prophylaxis (prevention) development program for lead antifungal product candidate, rezafungin for injection. Specifically, the QIDP designation is for the development of rezafungin for the prevention of invasive fungal infections in adults undergoing allogeneic bone marrow transplantation.
